RxDoctor Payments Data

Lin Chou, MD

Internal Medicine · Hillsborough, NJNPI 1083705560

Payments from drug & device makers

$1,984in general payments, 2019–2025

Across 78 payments — averaging $25.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$689
  • AstraZeneca$646
  • AbbVie$250
  • IBSA Pharma Inc.$161
  • Abiomed$75
  • GSK$61
  • plus $101 from 4 others

What the payments were for

  • Food & beverage$1,984100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk15$689
AstraZeneca15$646
AbbVie22$250
IBSA Pharma Inc.13$161
Abiomed2$75
GSK4$61
Merck3$37
Daiichi Sankyo Inc.2$28
Bayer1$21
Pfizer1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,984 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$146,922
Medicare patients
423
Services billed
2,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate18$21,272
EliquisApixaban16$16,878
SynthroidLevothyroxine Sodium29$3,180
Levothyroxine Sodium165$2,996
Rosuvastatin Calcium159$1,975
Atorvastatin Calcium164$1,504
Metoprolol Succinate60$1,473
Valsartan37$1,157
Omega-3 Acid Ethyl Esters11$887
Celecoxib12$887
Metformin Hcl ErMetformin Hcl96$885
Losartan Potassium110$883
Bupropion XlBupropion Hcl14$878
Zolpidem Tartrate64$687
Omeprazole56$615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$37$21,27218 claims
PfizerEliquis$14$16,87816 claims
AbbVieSynthroid$250$3,18029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Hillsborough

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →